ÍøºìºÚÁÏ

Skip to main content
(352) 265-8240

Paul L Crispen, MD : Research

Cancer Specialist (Oncologist), Urologist

Photo of Paul L Crispen
(352) 265-8240 MyUFÍøºìºÚÁÏ

Research at a glance

Top areas of exploration

  • Kidney Neoplasms , 39 publications
  • Carcinoma, Renal Cell , 28 publications
  • Nephrectomy , 20 publications
  • Prostatic Neoplasms , 16 publications

Research activity

95 publications

4,447 citations

Why is this important?

Active clinical trials

Intravesical Gemcitabine and Docetaxel for Low Grade Intermediate Risk Bladder Cancer

Bladder cancer is the 8th most common cancer in the ÍøºìºÚÁÏ Cancer Center catchment area and the 7th most common cancer presenting to UFÍøºìºÚÁÏ. Most newly diagnosed cases are stage I bladder cancer, which is defined by having no deep muscle…

Investigator
Paul L Crispen
Status
Accepting Candidates
Ages
18 Years - N/A
Sexes
All

My publications

95 publications

2024

Case report: A novel somatic SDHB variant in a patient with bladder paraganglioma.

Frontiers in endocrinology

•

2024

Efficacy of BCG for non-muscle invasive bladder cancer following nephroureterectomy for upper tract urothelial carcinoma.

Urologic oncology

•

2024

Efficacy of Intravesical Nadofaragene Firadenovec for Patients With Bacillus Calmette-Guérin-Unresponsive Nonmuscle-Invasive Bladder Cancer: 5-Year Follow-Up From a Phase 3 Trial.

The Journal of urology

•

2023

Background and Update for ECOG-ACRIN EA8212: A Randomized Phase 3 Trial of Intravesical Bacillus Calmette-Guérin (BCG) Versus Intravesical Docetaxel and Gemcitabine Treatment in BCG-naïve High-grade Non-muscle-invasive Bladder Cancer (BRIDGE).

European urology focus

•

2023

Editorial Comment.

The Journal of urology

•